XBIO: Xenetic Biosciences Price/Earnings to Growth Multiple

Symbol and logo of brand xeneticbio.com (XBIO)

Xenetic Biosciences (XBIO) relies on its own US-based centers and scientific foundation to develop oncology drugs. This PEG momentum chart provided by GURU.Markets demonstrates the market valuation of the business, where the current metric stands at 0.00. The high pricing power potential of the XCART platform is complemented by a streamlined network of contract laboratories, ensuring the uninterrupted execution of clinical trials.

Price/Earnings to Growth Ratio: Xenetic Biosciences Inc. (XBIO) for 07/04/2022 - 11/17/2026

Xenetic Bio (XBIO) - metric breakdowns and financial figures

General company analysis:XBIO - Xenetic Biosciences
Mass-produced product of Xenetic Biosciences Inc.

The specifics of Xenetic Biosciences (XBIO), with its preclinical oncology developments and lack of revenue, make the valuation of future profits critically dependent on the success of trials. This growth stock undervaluation ratio compares the current P/E to earnings growth rates, where a value below one signals that the asset is undervalued relative to its potential, helping to identify a mismatch between market expectations and actual results.

Competitors of Xenetic Biosciences

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen (URGN) - Price/Earnings to Growth Ratio|Bicara Bio - Growth-Adjusted Payback Ratio|PSNL (Personalis Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca, Inc. ERAS|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|Aura Biosciences Inc - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics CADL|accuray.com - PEG Multiple|SLS: Price/Earnings to Growth Ratio|ACTU (actuatetherapeutics.com) - Price/Earnings to Growth Multiple|CTOR - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio tuhurabio.com|PEG Multiple Protara Tx|Price/Earnings to Growth Multiple FATE (Fate Therapeutics Corp)|Price/Earnings to Growth Ratio WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Price/Earnings to Growth Multiple|Champions Oncology (CSBR) - Price to Earnings Adjusted for Growth Rate|XBiotech - PEG Multiple|CEL-SCI (CVM) - Price/Earnings to Growth Multiple|OS Therapies Inc (OSTX) - Price/Earnings to Growth Ratio|radiopharmtheranostics.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Artiva Biotherapeutics Inc.|Price to Earnings Adjusted for Growth Rate Adlai Nortye Ltd. ANL|PEG Multiple VERU|TPST - Price to Earnings Adjusted for Growth Rate|PEG Multiple XLO (Xilio Therapeutics)|RENB - Price/Earnings to Growth Multiple|muraloncology.com - PEG Multiple|KAPA - PEG Multiple|OKUR: PEG Multiple|Market Cap to Earnings and Growth Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - PEG Multiple|Apollomics, Inc. (APLM) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Growth-Adjusted Payback Ratio|PEG Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Price to Earnings Adjusted for Growth Rate|sunshinebiopharma.com - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple